

Myelo Therapeutics, as a member of the COUNTERACT network, selected to receive Multi-Million Euro Grant from the European Defense Fund for the Development of Medical Countermeasures

BERLIN, GERMANY, August 04, 2022 – Myelo Therapeutics GmbH, as a member of a pan-European consortium of research and industry partners, has successfully entered into the grant agreement negotiation phase potentially providing up to 17 million Euro for the development of its medical countermeasure (MCM) against acute radiation syndrome. The program provides the opportunity to advance its MCM candidate towards a marketing authorization application at the end of a four-years funding period.

The Berlin-based small and medium-sized enterprise (SME) Myelo Therapeutics GmbH started 2019 its countermeasure program with the support of the U.S. National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. “Our international team of scientists is uniquely positioned to establish a comprehensive research network and develop novel countermeasures for deployment in EU and NATO territory”, commented Dirk Pleimes (CEO/CSO, Myelo Therapeutics GmbH).

Beyond its lead molecule’s potential as a medical countermeasures, Myelo Therapeutics’ MCM portfolio has several promising clinical applications in mitigating radiation and chemotherapy-induced toxicity in nuclear medicine and (radiation) oncology.

The funds are part of a 49 million EUR grant that the European Defense Fund considers allocating to the consortium led by the French Commissariat à l’énergie Atomique et aux Energies Alternatives (CEA). The project "European agile network for medical COUNTERmeasures Against CBRN Threats" (COUNTERACT) aims to establish a robust and agile network within the EU to be capable of developing and deploying medical countermeasures (MCMs) against major Chemical, Biological, Radiological, and Nuclear (CRBN) threats such as terror plots, nuclear accidents, weapon development and epidemics caused by emerging or re-emerging high consequence pathogens. COUNTERACT will increase EU preparedness for immediate response to such threats (https://defence-industry-space.ec.europa.eu/funding-and-grants/calls-proposals/european-defence-fund-2021-calls-proposals-results_en).

About Myelo Therapeutics: Myelo Therapeutics GmbH is a pharmaceutical company based in Berlin, Germany, developing innovative medical countermeasure treatments against Chemical, Biological, Radiological, and Nuclear (CRBN) threats and Supportive Care therapies in Oncology and Nuclear Medicine. Myelo Therapeutics GmbH is an affiliate of Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700, SDAX). For more information, visit www.myelotherapeutics.com.

About Acute Radiation Syndrome: ARS, also known as radiation toxicity or radiation sickness, is an acute illness that presents after exposure of large portions of the body to high levels of radiation, like those that might be experienced during a radiological/nuclear incident or attack. The primary manifestation of ARS is the depletion of hematopoietic stem and progenitor cells, constituting one of the major causes of mortality.